insulin lispro biosimilar Admelog
Selected indexed studies
- Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. (J Diabetes Sci Technol, 2018) [PMID:29359575]
- SAR342434 - an insulin biosimilar for the treatment of type II diabetes. (Expert Opin Biol Ther, 2018) [PMID:30295083]
- Biosimilars and Novel Insulins. (Am J Ther, 2020) [PMID:31764128]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. (2018) pubmed
- SAR342434 - an insulin biosimilar for the treatment of type II diabetes. (2018) pubmed
- Biosimilars and Novel Insulins. (2020) pubmed
- Update on Biosimilar Insulins: A US Perspective. (2020) pubmed
- Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan-Approved Humalog Insulin Lispro in Healthy Japanese Subjects. (2022) pubmed
- Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway. (2019) pubmed
- In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps. (2023) pubmed
- Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. (2018) pubmed
- Newer Insulin Preparations and Insulin Analogs. (2024) pubmed
- Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. (2017) pubmed